David N. Cook - Feb 23, 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc. (FMTX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Jeannette Potts, as Attorney-in-Fact
Stock symbol
FMTX
Transactions as of
Feb 23, 2022
Transactions value $
-$34,524
Form type
4
Date filed
2/25/2022, 04:09 PM
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FMTX Common Stock Sale -$34.5K -3.53K -17.66% $9.78 16.5K Feb 23, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.61 to $10.005. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Remarks:

In a Form 4 filed by the reporting person on March 2, 2021, the box indicating "no longer subject to Section 16" was inadvertently checked. The reporting person has remained subject to Section 16, and all changes in beneficial ownership subsequent to such Form 4 have been properly reported on a timely basis.